← SEC 公告列表 | CRVO SEC 公告 | CervoMed Inc.（CRVO）

重大事件 即時報告 8-K 2026-06-15

CervoMed 發佈業務及臨床進展演示文件 屬例行FD披露

於 SEC 網站開啟原文

AI 繁中摘要

📄 **申報類型：8-K（2026年6月15日）** **公司：CervoMed Inc.（納斯達克代碼：CRVO）** CervoMed 於2026年6月15日提交一份 8-K 表格，主要涉及 **Regulation FD 披露（項目 7.01）**。公司在其官方網站 **www.cervomed.com** 的「投資者 – 活動與簡報」欄目上發佈了一份包含業務、臨床研究、開發計劃及財務狀況等資訊的演示文件。該演示文件可能在不作重大修改的情況下，用於與投資者、分析師及其他相關方的會議及簡報。 公司明確表示，沒有義務公開更新或修訂該演示文件中的資訊，除非法律另有規定。此外，該 8-K 中的披露內容 **不被視為** 根據《1934年證券交易法》第18條“歸檔”，也不會被視為納入任何根據《1933年證券法》或《交易法》提交的登記聲明或其他文件中，除非該文件明確引用。 **對投資者的潛在影響**： - 此次申報屬例行披露，並未公佈重大新事件或業績數字。 - 建議投資者直接查閱公司網站上的演示文件，以了解最新臨床進展及戰略方向。 - 屬於非強制性披露，不構成對未來表現的保證。 **關鍵注意點**：無具體財務數字或季度業績提及，重點在於 FD 合規及資訊傳播渠道。
展開英文正文 
crvo20260615_8k.htm
 
 
 

false
0001053691

0001053691

2026-06-15
2026-06-15

 
 
  

 UNITED STATES
 

 SECURITIES AND EXCHANGE COMMISSION
 

 Washington, D.C. 20549
 

  

 
  

 FORM 8-K
 

  

 
  

 CURRENT REPORT
 

 Pursuant to Section 13 or 15(d)
 

 of The Securities Exchange Act of 1934
 

  

 June 15, 2026
 

 Date of Report (Date of earliest event reported)
 

  

 
  

 CervoMed Inc.
 

 (Exact name of registrant as specified in its charter) 

  

 
 
 Delaware
001-37942
30-0645032

 

 (State or other jurisdiction 
of incorporation) 
(Commission 
File Number) 
(I.R.S. Employer 
Identification No.) 

 

  
 
 

 

 20 Park Plaza, Suite 424
Boston, Massachusetts
02116

 

 (Address of principal executive offices) 
(Zip Code) 

 

 
  

 Registrant’s telephone number, including area code: (617) 744-4400
 

  

 Not applicable
 

 (Former name or former address, if changed since last report) 

  

 
  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

 
 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 
  

 
 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 
  

 
 ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 
  

 
 ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
  

 
 Title of each class 
 
Trading 
Symbol(s) 
 
Name of each exchange 
on which registered 

 

 Common Stock, $0.001 par value
 
CRVO
 
NASDAQ Capital Market

 

 
  

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging growth company ☐ 

  

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

  

 
 
  

 
 

 
 

 

  

 
 Item 7.01Regulation FD Disclosure 

 

 
  

 Certain information concerning the business, clinical studies, development plans, financial position and related matters of CervoMed Inc. (the “Company,” “we,” or “us”) has been made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.

  

 The information contained in the presentation is summary information that is intended to be considered in the context of the Company’s filings with the SEC and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K.

  

 The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

  

  

 
 Item 9.01  Financial Statements and Exhibits

 

 
  

 
 (d)
Exhibits

 

 
  

 
 Exhibit No. Description

 

 104
Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
  

 
 

 
 

 

  

 SIGNATURES
 

  

 Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

 
 Date: June 15, 2026    
CervoMed Inc.
 

 

  
 
 
 

 

  
By:
/s/ William Elder
 

 

  
Name:
William Elder
 

 

  
Title:
Chief Financial Officer & General Counsel